Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Accounts Payables: 2009-2024

Historic Accounts Payables for Pediatrix Medical (MD) over the last 9 years, with FY2024 value amounting to $398.7 million.

  • Pediatrix Medical's Accounts Payables changed N/A to $352.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.2 million, marking a year-over-year change of. This contributed to the annual value of $398.7 million for FY2024, which is 1365.23% up from last year.
  • As of FY2024, Pediatrix Medical's Accounts Payables stood at $398.7 million, which was up 1365.23% from $350.8 million recorded in FY2023.
  • Pediatrix Medical's 5-year Accounts Payables high stood at $398.7 million for FY2024, and its period low was $350.8 million during FY2023.
  • Moreover, its 3-year median value for Accounts Payables was $374.2 million (2022), whereas its average is $374.6 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 626.01% in 2023, then soared by 1365.23% in 2024.
  • Pediatrix Medical's Accounts Payables (Annual) stood at $374.2 million in 2022, then dropped by 6.26% to $350.8 million in 2023, then grew by 13.65% to $398.7 million in 2024.
  • Its Accounts Payables was $398.7 million in FY2024, compared to $350.8 million in FY2023 and $374.2 million in FY2022.